Galectin Therapeutics (GALT) Total Non-Current Liabilities (2010 - 2026)

Galectin Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $143.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 17.56% year-over-year to $143.0 million; the TTM figure through Mar 2026 stood at $143.0 million (up 17.56% YoY), while the FY2025 annual figure was $141.8 million, up 17.68% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $143.0 million, up from $141.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $143.0 million in Q1 2026, with the low at $39.4 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $96.9 million (2024), against an average of $93.5 million.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 745.31% in 2022, then advanced 13.47% in 2025.
• Galectin Therapeutics' Total Non-Current Liabilities stood at $53.3 million in 2022, then soared by 65.23% to $88.0 million in 2023, then surged by 36.88% to $120.5 million in 2024, then climbed by 17.68% to $141.8 million in 2025, then climbed by 0.88% to $143.0 million in 2026.
• Business Quant data shows GALT's Total Non-Current Liabilities at $143.0 million in Q1 2026, $141.8 million in Q4 2025, and $136.4 million in Q3 2025.